1Department of Surgical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India
2Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India
3Department of Pathology, Asian Institute of Gastroenterology, Hyderabad, India
© Copyright 2023. Korean Association for the Study of Intestinal Diseases.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Funding Source
The authors received no financial support for the research, authorship, and/or publication of this article.
Conflict of Interest
No potential conflict of interest relevant to this article was reported.
Data Availability Statement
Not applicable.
Author Contributions
Conceptualization: Rao GV, Pal P. Data curation: Pal P. Formal analysis: Pal P. Investigation: Pal P, Sekaran A. Methodology: Rao GV, Pal P. Project administration: Rao GV, Tandan M. Supervision: Rebala P, Tandan M, Reddy DN. Visualization: Rao GV, Rebala P, Tandan M, Reddy DN. Writing - original draft: Pal P. Writing - review & editing: all authors. Approval of final manuscript: all authors.
Definitions | |
---|---|
Clinical recurrence | Recurrence of symptoms related to Crohn’s disease (e.g., pain abdomen, loose stools, weight loss, etc.) confirmed by radiological examination or endoscopy. |
Endoscopic recurrence | Anastomotic Rutgeerts score of i2 or higher (i.e., more than 5 aphthous lesions with intervening normal mucosa, diffuse aphthous ulcers/inflammation, larger ulcers, nodules or luminal narrowing or lesions not confined to the ileo-colonic anastomosis). |
Surgical recurrence | Crohn’s disease associated complications warranting repeat resection need for a redo resection. |
Early recurrence | Recurrence in in any form (clinical, endoscopic, or surgical) within 12 months of the first resection. |
Positive resection margin | Presence of the following in the proximal or distal resection margin: architectural distortion (e.g., crypt branching, crypt loss, etc.), cryptitis, erosions, ulcerations, fibrosis, granulomas, neuronal hyperplasia, Paneth cell metaplasia, transmural inflammation with lymphoid aggregates, and basal plasmacytosis. |
Granuloma | Well-defined non-caseating granuloma (i.e., clusters of macrophages and lymphocytes) without associated foreign bodies. |
Plexitis | Inflammatory cells (lymphocytes, mastocytes, or eosinophils) infiltration into or adjacent to enteric nerve bundles and ganglions evident on hematoxylin and eosin stain and/or immunohistochemistry. Subdivision: myenteric plexitis or submucosal plexitis. |
Components of the CNM staging | Description | |||
---|---|---|---|---|
C (Crohn’s primary site: factors within intestinal wall) | G (Granuloma) | |||
G0 | No granuloma at resection specimen or margin | |||
G1 | Granuloma present at margin/specimen | |||
Subcategory | ||||
A | Granuloma at resection specimen | |||
B | Granuloma at resection margin | |||
C | Granuloma at both resection specimen and margin | |||
R (Resection margin) | ||||
R0 | Resection with negative microscopic margins at both ends | |||
R1 | Resection with positive microscopic margins | |||
Subcategory | ||||
A | Involvement of proximal margin | |||
B | Involvement of distal margin | |||
C | Involvement of both proximal and distal margin | |||
I (Infiltration depth) | ||||
I1 | Involving submucosa | |||
I2 | Involving muscularis propria | |||
I3 | Involving subserosa or non-peritonealized perirectal or pericolic tissue | |||
I4 | Involving adjacent organ or structures and/or perforated visceral peritoneum | |||
P (Plexitis) | ||||
P0 | No plexitis | |||
P1 | Mild plexitis (< 4/HPF) | |||
P2 | Moderate plexitis (4-9/HPF) | |||
P3 | Severe plexitis (> 9 /HPF) | |||
Subcategory | ||||
A | Plexitis in myenteric plexus | |||
B | Plexitis in submucosal plexus | |||
C | Plexitis in both myenteric and submucosal plexus | |||
Final C staging | C1 | Any 1 of the following is present: granuloma, positive resection margin, plexitis or transmural involvement | ||
C2 | Any 2 of the following is present: granuloma, positive resection margin, plexitis or transmural involvement | |||
C3 | Any 3 of the following is present: granuloma, positive resection margin, plexitis or transmural involvement | |||
C4 | All 4 of granuloma, positive resection margin, plexitis and transmural involvement | |||
N (nodal granuloma) | Nx | Regional nodes cannot be assessed | ||
N0 | No granulomas in regional lymph nodes | |||
N1 | Granulomas in regional lymph nodes | |||
M (mesentery involvement) | M0 | Mesentery not involved | ||
M1 | Mesentery involved (microscopic evidence in the form of thickening of the surface mesothelium/submesothelial/interlobular connective tissue with or without presence of connective tissue septations) but no visible fat wrapping/mesenteric thickening | |||
M2 | Grossly visible mesenteric involvement in the form of fat wrapping and mesenteric thickening | |||
Subcategory | ||||
A | Minimal fat wrapping and mesenteric thickening | |||
B | Fat wrapping < 25% of circumference with mesenteric thickening (adipo-vascular pedicle or pan-mesenteric) | |||
C | Fat wrapping > 25% of circumference with pan-mesenteric thickening |
CNM, Crohn’s primary site, nodes, mesentery; HPF, high-power field.